ProShares Ultra NASDAQ Biotechnology
24 hedge funds and large institutions have $11.6M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
48% more capital invested
Capital invested by funds: $7.83M → $11.6M (+$3.79M)
14% more call options, than puts
Call options by funds: $2.54M | Put options by funds: $2.24M
4.14% more ownership
Funds ownership: 7.14% → 11.28% (+4.1%)
4% less funds holding
Funds holding: 25 → 24 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$2.5M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.29M |
| 3 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
+$915K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$653K |
| 5 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$503K |
| 2 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$445K |
| 3 |
Jane Street
New York
|
-$439K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$169K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$82.2K |
BIB Hedge Fund Activity: Q1 2023 in Review
24 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2023, worth a combined $11.6M — up 48% from $7.83M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIB and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was IMC Chicago, opening a new position worth an estimated $2.5M. The largest seller was Tower Research Capital (TRC), cutting an estimated $503K.
- 24 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2023, down from 25 in Q4 2022.
- Funds reported $11.6M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2023, up 48% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2023 and 7 closed out, a net change of -1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2023 was IMC Chicago, an estimated $2.5M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2023 was Tower Research Capital (TRC), an estimated $503K sold.
Based on aggregated 13F filings for Q1 2023.